October 03, 2021 08:00 PM Eastern Daylight Time
BUSINESS WIRE
Incyte annonce les résultats complets de son programme TRuE-V de Phase 3 évaluant la crème au ruxolitinib (Opzelura™) chez des patients atteints de vitiligo
Tweet
View Full Size
Download
Full Size
JPEG
,
753
x
548
,
93.9 KB
Small
JPEG
,
480
x
349
,
62.1 KB
Preview
JPEG
,
144
x
105
,
14.2 KB
Thumbnail
JPEG
,
96
x
70
,
8.7 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Incyte annonce les résultats complets de son pr...